Showing results (51-60 of 83) with videos related to
Sort By:
Pageof 9
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|July 29, 2010
International Society for Clinical Densitometry official positions: Asia-Pacific Region consensusAnnie W C Kung, Chih-Hsing Wu, Akira Itabashi, et al.Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 17, 2005
A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronateJean-Yves Reginster, Dieter Felsenberg, Cyrus Cooper, et al.Seminars in Arthritis and Rheumatism|August 5, 2006
The effects of antifracture therapies on the components of bone strength: assessment of fracture risk today and in the futureK Shawn Davison, Kerry Siminoski, J D Adachi, et al.Seminars in Arthritis and Rheumatism|August 5, 2006
Bone strength: the whole is greater than the sum of its partsK Shawn Davison, Kerry Siminoski, J D Adachi, et al.Current Osteoporosis Reports|March 26, 2013
High-resolution peripheral quantitative computed tomography for the assessment of bone strength and structure: a review by the Canadian Bone Strength Working GroupAngela M Cheung, Jonathan D Adachi, David A Hanley, et al.Archives of Osteoporosis|January 20, 2019
Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trialSalvatore Minisola, Fernando Marin, David L Kendler, et al.Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|May 11, 2012
Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosisMichael R McClung, Jose R Zanchetta, Arne Høiseth, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 13, 2018
Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO TrialPiet Geusens, Fernando Marin, David L Kendler, et al.Lancet (London, England)|November 14, 2017
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trialDavid L Kendler, Fernando Marin, Cristiano A F Zerbini, et al.The Journal of Clinical Endocrinology and Metabolism|February 10, 2016
Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis StudyDavid W Dempster, Hua Zhou, Robert R Recker, et al.Pageof 9